Therapy for Crohn’s Disease: a Review of Recent Developments
Purpose of Review
To review recent advances in the treatment of Crohn’s disease.
Several key advances are highlighted, including the increasing role of treatment algorithms and where new therapies can be used most effectively, the appropriate use of therapeutic drug monitoring, optimal management of post-surgical patients, and the role of multi-disciplinary clinics.
The last several years have seen a number of exciting developments in the field of Crohn’s therapy. This review covers research advances including updated treatment algorithms focusing on identifying patient risk as well as the role of drug monitoring in managing the disease. We also review the optimal management of post-surgical patients as well as new biologics and biosimilars. Finally, we describe innovations in care delivery including multi-disciplinary clinics and emerging evidence from developing therapeutics.
KeywordsCrohn’s IBD Therapy Treatment Management
Compliance with Ethical Standards
Conflict of Interest
Gil Melmed reports personal fees from Abbvie, Celgene, Janssen, Pfizer, Samsung Bioepis, Takeda for consultation and service on advisory boards, outside the submitted work. Gregory Eustace declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82.CrossRefPubMedGoogle Scholar
- 12.• Colombel, J.-F., et al., Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet, 2017. Demonstrated significantly higher rates of endoscopic healing in patients randomized to therapeutic escalation with adalimumab based on clinical symptoms plus biomarkers compared to those escalated based on clinical symptoms alone. Google Scholar
- 13.Cosnes, J., et al., Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology, 2013. 145(4): p. 758–65.e2; quiz e14–5.Google Scholar
- 14.• Panes J, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74.e1. Demonstrated no difference between azathioprine and placebo in achieving steroid-free remission (CDAI < 150 and no requirement for steroids);however, the azathioprine group did have lower relapse rates (CDAI > 220). CrossRefPubMedGoogle Scholar
- 15.Feuerstein JD, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 153(3):827–34.Google Scholar
- 17.Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.• Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine. 2013;369(8):711–21. Demonstrated higher rates of clinical remission at week six as well as higher rates of maintained remission at week 52 among initial responders to vedolizumab. CrossRefPubMedGoogle Scholar
- 19.Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohn's Colitis. 2017;11(4):412–24.Google Scholar
- 21.• Feagan BG, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60. Positive trial for clinical response to ustekinumab in both TNF experienced and naïve arms by week six. Rates of continued remission at week 44 were significantly higher in the treatment arm. CrossRefPubMedGoogle Scholar
- 22.Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–302.CrossRefPubMedGoogle Scholar
- 25.Hazlewood, G.S., et al., Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology, 2015. 148(2): p. 344–54 e5; quiz e14–5.Google Scholar
- 27.Reenaers, C., et al., Outcomes 7 years after infliximab withdrawal for patients with Crohn’s disease in sustained remission. Clin Gastroenterol Hepatol, 2017.Google Scholar
- 28.Torres, J., et al., Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 149(7): p. 1716-1730.Google Scholar
- 34.• De Cruz, P., et al., Crohn’s disease management after intestinal resection: a randomised trial. Lancet, 2015. 385(9976): p. 1406–17. Showed a significantly lower proportion of patients who had appropriate therapy escalation at a six month post-operative colonoscopy had evidence of endoscopic recurrence at 18 months than patients who were not re-evaluated at six months. Google Scholar
- 38.Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Pentek, M., Z. Zrubka, and L. Gulacsi, The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des, 2017.Google Scholar
- 40.Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–57.CrossRefPubMedGoogle Scholar
- 41.Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.CrossRefPubMedGoogle Scholar
- 42.Kim, Y.H., Ye B.D., Pesegova M., Alexeeva O., Osipenko M., Lahat A., Dorofeyev A., Salamon A., Fishman S., Levchenko O., Cheon J.H., Scribano M.L., Mateescu R.B., Lee K.M., Eun C.S., Lee S.J., Lee S.Y., DOP061 phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. J Crohn's Colitis, 2017. 11(suppl_1): p. S62-S62.Google Scholar
- 43.Ben-Horin, S., et al., Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut, 2015.Google Scholar
- 45.Feagan BG, Sandborn WJ, D’Haens G, Panés J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709.CrossRefPubMedGoogle Scholar
- 48.Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–75.CrossRefPubMedGoogle Scholar